News Release 5th January 2004

De Novo Pharmaceuticals Announces Collaboration with Lilly

De Novo Pharmaceuticals today announced that it has entered into a licensing agreement with Eli Lilly and Company (Indianapolis, USA). Under the terms of the agreement De Novo will license its proprietary algorithm based platform SkelGen® on a non-exclusive basis for research on undisclosed targets belonging to Lilly.
SkelGen is a platform that uses structural information on drug targets to generate potential new drugs by computer modelling.

Drs Bart Wuurman, Chief Executive Officer of De Novo, said: “We are delighted to be working with Lilly. This is another major pharmaceutical company to recognise the value that SkelGen can potentially deliver to their drug discovery process. This agreement is precisely in line with our recently announced strategy of focussing on commercial development and partnering of our excellent computational chemistry platforms.”

De Novo Pharmaceuticals Ltd.
De Novo Pharmaceuticals is a world leader in the field of in-silico drug design located in Cambridge UK. Its proprietary algorithm based platform SkelGen can make the drug discovery process faster, cheaper and more effective, with the added benefit that it can lead to patentable molecules against disease targets whilst ruling out molecular structures that are too complicated to synthesize commercially.

De Novo is currently seeking collaborations with biotech and pharma companies.

< Back to archive